Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

被引:118
|
作者
Taher, Ali [1 ]
El-Beshlawy, Amal [2 ]
Elalfy, Mohsen S. [3 ]
Al Zir, Kusai [4 ]
Daar, Shahina [5 ]
Habr, Dany [8 ]
Kriemler-Krahn, Ulrike [6 ]
Hmissi, Abdel [6 ]
Al Jefri, Abdullah [7 ]
机构
[1] Amer Univ Beirut, Div Oncol, Dept Internal Med, Med Ctr, Beirut 11072020, Lebanon
[2] Cairo Univ, Cairo, Egypt
[3] Ain Shams Univ, Cairo, Egypt
[4] Natl Thalassemia Ctr, Damascus, Syria
[5] Sultan Qaboos Univ, Muscat, Oman
[6] Novartis Pharma AG, Basel, Switzerland
[7] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
[8] Novartis Pharmaceut, E Hanover, NJ USA
关键词
iron chelation; deferasirox; beta-thalassaemia; transfusional iron overload; COMPLICATIONS; SURVIVAL; THERAPY;
D O I
10.1111/j.1600-0609.2009.01228.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients >= 2 yr with beta-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of >= 3 mg Fe/g dry weight (dw) if baseline LIC was >= 10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to < 10 mg Fe/g dw. Overall, 233/237 enrolled patients completed 1 yr's treatment. Mean baseline LIC was 18.0 +/- 9.1 mg Fe/g dw, while median serum ferritin was 3356 ng/mL. After 1 yr's deferasirox treatment, the intent-to-treat population experienced a significant treatment success rate of 57.0% (P = 0.016) and a mean reduction in LIC of 3.4 mg Fe/g dw. Changes in serum ferritin appeared to parallel dose increases at around 24 wk. Most patients (78.1%) underwent dose increases above 20 mg/kg/d, primarily to 30 mg/kg/d. Drug-related adverse events were mostly mild to moderate and resolved without discontinuing treatment. The results of the ESCALATOR study in primarily heavily iron-overloaded patients confirm previous observations in patients with beta-thalassaemia, highlighting the importance of timely deferasirox dose adjustments based on serum ferritin levels and transfusional iron intake to ensure patients achieve their therapeutic goal of maintenance or reduction in iron burden.
引用
收藏
页码:458 / 465
页数:8
相关论文
共 50 条
  • [1] DEFERASIROX SIGNIFICANTLY REDUCES IRON BURDEN IN HEAVILY IRON-OVERLOADED PATIENTS WITH β-THALASSAEMIA: 2.7 YEAR RESULTS FROM THE ESCALATOR STUDY
    Taher, A.
    El-Beshlawy, A.
    Elalfy, M.
    Al Zir, K.
    Daar, S.
    Habr, D.
    Kriemler-Krahn, U.
    Roubert, B.
    Al Jefri, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 82 - 82
  • [2] Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
    Daar, Shahina
    Pathare, Anil
    Nick, Hanspeter
    Kriemler-Krahn, Ulrike
    Hmissi, Abdel
    Habr, Dany
    Taher, Ali
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (06) : 454 - 457
  • [3] IMPROVED TREATMENT SATISFACTION AND CONVENIENCE WITH DEFERASIROX IN IRON-OVERLOADED PATIENTS WITH β-THALASSAEMIA: RESULTS FROM ESCALATOR TRIAL
    Taher, A.
    Al Jefri, A.
    Elalfy, M. S.
    Al Zir, K.
    Daar, S.
    Damanhouri, G.
    Baladi, J-F
    Kriemler-Krahn, U.
    El-Beshlawy, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 318 - 319
  • [4] Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
    Salem, Ahmed
    Desai, Payal
    Elgebaly, Ahmed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [5] Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial
    Taher, Ali
    Al Jefri, Abdullah
    Elalfy, Mohsen Saleh
    Al Zir, Kusai
    Daar, Shahina
    Rofail, Diana
    Baladi, Jean Francois
    Habr, Dany
    Kriemler-Krahn, Ulrike
    El-Beshlawy, Amal
    ACTA HAEMATOLOGICA, 2010, 123 (04) : 220 - 225
  • [6] Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil
    Wood, John C.
    Otto-Duessel, Maya
    Gonzalez, Ignacio
    Aguilar, Michelle I.
    Shimada, Hiro
    Nick, Hanspeter
    Nelson, Marvin
    Moats, Rex
    TRANSLATIONAL RESEARCH, 2006, 148 (05) : 272 - 280
  • [7] Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella)
    Bergeron, RJ
    Wiegand, J
    Weimar, WR
    Lindstrom, TC
    Fannin, TL
    Ratliff-Thompson, K
    COMPARATIVE MEDICINE, 2004, 54 (06) : 664 - 672
  • [8] The administration of deferasirox in an iron-overloaded dialysis patient
    Tsai, Ching-Wei
    Yang, Feng-Jung
    Huang, Chun-Chieh
    Kuo, Chin-Chi
    Chen, Yung-Ming
    HEMODIALYSIS INTERNATIONAL, 2013, 17 (01) : 131 - 133
  • [9] Chelator-induced iron excretion in iron-overloaded marmosets
    Sergejew, T
    Forgiarini, P
    Schnebli, HP
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (04) : 985 - 992
  • [10] A dose escalation study of the pharmacokinetics, safety & efficacy of deferitrin an oral iron chelator in beta thalassaemia patients
    Galanello, R.
    Forni, G.
    Jones, A.
    Kelly, A.
    Willemsen, A.
    He, X.
    Johnston, A.
    Fuller, D.
    Donovan, J.
    Piga, Antonio
    BLOOD, 2007, 110 (11) : 784A - 785A